GB0921288D0 - Therapies for preventing or suppressing clostridium difficile infection - Google Patents

Therapies for preventing or suppressing clostridium difficile infection

Info

Publication number
GB0921288D0
GB0921288D0 GBGB0921288.7A GB0921288A GB0921288D0 GB 0921288 D0 GB0921288 D0 GB 0921288D0 GB 0921288 A GB0921288 A GB 0921288A GB 0921288 D0 GB0921288 D0 GB 0921288D0
Authority
GB
United Kingdom
Prior art keywords
therapies
preventing
clostridium difficile
difficile infection
suppressing
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB0921288.7A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Micropharm Ltd
Public Health England
Original Assignee
Health Protection Agency
Micropharm Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Health Protection Agency, Micropharm Ltd filed Critical Health Protection Agency
Priority to GBGB0921288.7A priority Critical patent/GB0921288D0/en
Publication of GB0921288D0 publication Critical patent/GB0921288D0/en
Priority to MYPI2012002466A priority patent/MY158712A/en
Priority to JP2012541584A priority patent/JP5877161B2/ja
Priority to EP10787170.9A priority patent/EP2506877B1/en
Priority to CA2782639A priority patent/CA2782639C/en
Priority to BR112012013496A priority patent/BR112012013496A2/pt
Priority to PCT/GB2010/052035 priority patent/WO2011067616A1/en
Priority to SG2012039616A priority patent/SG181127A1/en
Priority to CN2010800537789A priority patent/CN102740889A/zh
Priority to AU2010325764A priority patent/AU2010325764B2/en
Priority to US13/513,555 priority patent/US8921529B2/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria
    • C07K16/1282—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria from Clostridium (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/542—Mucosal route oral/gastrointestinal
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
GBGB0921288.7A 2009-12-04 2009-12-04 Therapies for preventing or suppressing clostridium difficile infection Ceased GB0921288D0 (en)

Priority Applications (11)

Application Number Priority Date Filing Date Title
GBGB0921288.7A GB0921288D0 (en) 2009-12-04 2009-12-04 Therapies for preventing or suppressing clostridium difficile infection
US13/513,555 US8921529B2 (en) 2009-12-04 2010-12-06 Therapies for preventing or suppressing Clostridium difficile infection
CA2782639A CA2782639C (en) 2009-12-04 2010-12-06 Therapies for preventing or suppressing clostridium difficile infection
JP2012541584A JP5877161B2 (ja) 2009-12-04 2010-12-06 クロストリジウム・ディフィシル感染を予防または抑制するための治療法
EP10787170.9A EP2506877B1 (en) 2009-12-04 2010-12-06 Therapies for preventing or suppressing clostridium difficile infection
MYPI2012002466A MY158712A (en) 2009-12-04 2010-12-06 Therapies for preventnig or suppressing clostridium difficile infection
BR112012013496A BR112012013496A2 (pt) 2009-12-04 2010-12-06 "composição de anticorpo para a prevenção ou supressão da infecção por clostridium difficile e composição farmacêutica para a aplicação oral".
PCT/GB2010/052035 WO2011067616A1 (en) 2009-12-04 2010-12-06 Therapies for preventing or suppressing clostridium difficile infection
SG2012039616A SG181127A1 (en) 2009-12-04 2010-12-06 Therapies for preventing or suppressing clostridium difficile infection
CN2010800537789A CN102740889A (zh) 2009-12-04 2010-12-06 用于预防或抑制艰难梭菌感染的疗法
AU2010325764A AU2010325764B2 (en) 2009-12-04 2010-12-06 Therapies for preventing or suppressing Clostridium difficile infection

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0921288.7A GB0921288D0 (en) 2009-12-04 2009-12-04 Therapies for preventing or suppressing clostridium difficile infection

Publications (1)

Publication Number Publication Date
GB0921288D0 true GB0921288D0 (en) 2010-01-20

Family

ID=41641956

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB0921288.7A Ceased GB0921288D0 (en) 2009-12-04 2009-12-04 Therapies for preventing or suppressing clostridium difficile infection

Country Status (10)

Country Link
US (1) US8921529B2 (enExample)
EP (1) EP2506877B1 (enExample)
JP (1) JP5877161B2 (enExample)
CN (1) CN102740889A (enExample)
BR (1) BR112012013496A2 (enExample)
CA (1) CA2782639C (enExample)
GB (1) GB0921288D0 (enExample)
MY (1) MY158712A (enExample)
SG (1) SG181127A1 (enExample)
WO (1) WO2011067616A1 (enExample)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5740714B2 (ja) 2009-02-20 2015-06-24 ヘルス プロテクション エージェンシー クロストリジウム・ディフィシル（Ｃｌｏｓｔｒｉｄｉｕｍｄｉｆｆｉｃｉｌｅ）毒素に対する抗体
GB0921288D0 (en) 2009-12-04 2010-01-20 Health Prot Agency Therapies for preventing or suppressing clostridium difficile infection
CN103957931B (zh) * 2010-09-03 2017-10-24 瓦尔内瓦奥地利有限责任公司 艰难梭状芽胞杆菌毒素a和毒素b蛋白的分离多肽及其用途
GB201016742D0 (en) 2010-10-05 2010-11-17 Health Prot Agency Clostridium difficile antigens
SI3505531T1 (sl) 2011-04-22 2024-02-29 Wyeth Llc Kompozicije, povezane z mutantnim toksinom clostridium difficile in njegovimii metodami
CA2845884A1 (en) 2011-08-22 2013-02-28 Cangene Corporation Clostridium difficile antibodies
MX2014006630A (es) 2011-12-08 2014-07-09 Novartis Ag Vacuna a base toxina clostridium difficile.
DE102011121237A1 (de) * 2011-12-14 2013-06-20 Universitätsklinikum Hamburg-Eppendorf Einzeldomänen-Antikörper gegen Clostridium difficile Toxin CDTa
AR089797A1 (es) * 2012-01-27 2014-09-17 Merck Sharp & Dohme Vacunas contra clostridum difficile que comprenden toxinas recombinantes
BR122016023101B1 (pt) 2012-10-21 2022-03-22 Pfizer Inc Polipeptídeo, composição imunogênica que o compreende, bem como célula recombinante derivada de clostridium difficile
US20160002278A1 (en) 2013-03-08 2016-01-07 Cipla Limited Pharmaceutical Compositions for Rectal Administration
CN105308066A (zh) * 2013-03-15 2016-02-03 圣诺菲·帕斯图尔公司 类毒素、组合物和相关的方法
US10226523B2 (en) * 2013-04-22 2019-03-12 The Board Of Regents Of The University Of Oklahoma Clostridium difficile vaccine and methods of use
MX2015017257A (es) 2013-06-14 2016-11-11 Sanofi Pasteur Inc Composiciones y metodos de inmunizar contra clostridium difficile.
EP2957570B1 (en) * 2014-06-20 2019-04-17 Immunimed Inc. Polyclonal antibodies against clostridium difficile and uses thereof
US10513552B2 (en) 2014-06-20 2019-12-24 Immunimed Inc. Use of polyclonal antibodies against clostridium difficile for treatment of inflammatory bowel disease
CA2954087C (en) * 2014-07-25 2023-09-19 Biosynth S.R.L. Glycoconjugate vaccines comprising basic units of a molecular construct expressing built-in multiple epitopes for the formulation of a broad-spectrum vaccine against infections due to enteropathogenic bacteria
EP3121272A1 (en) * 2015-07-24 2017-01-25 Zymetech ehf. Novel fish trypsin isoforms and their use
WO2017173068A1 (en) * 2016-03-30 2017-10-05 University Of Maryland, Baltimore Microparticulate system for colonic drug delivery
GB201701404D0 (en) 2017-01-27 2017-03-15 Micropharm Ltd Therapies for treating inflammatory disorders
GB202019817D0 (en) * 2020-12-15 2021-01-27 Univ Oxford Innovation Ltd Ligand-binding polypeptides and uses thereof

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS608225A (ja) 1983-06-29 1985-01-17 Kowa Co 腸管吸収医薬組成物
US5601823A (en) * 1989-10-31 1997-02-11 Ophidian Pharmaceuticals, Inc. Avian antitoxins to clostridium difficle toxin A
CA2197714A1 (en) 1994-09-06 1996-03-14 Immucell Corporation Therapeutic treatment of clostridium difficile associated diseases
EP1041149B8 (en) * 1994-10-24 2007-10-03 Allergan, Inc. Vaccine and antitoxin for treatment and prevention of C. difficile disease
US6096310A (en) 1997-04-15 2000-08-01 Bier; Milan Oral immunotherapy of bacterial overgrowth
AU746859B2 (en) 1997-06-20 2002-05-02 Imperial College Of Science, Technology And Medicine Immonogenic fragments of toxin a of clostridium difficile
US6214341B1 (en) 1997-10-20 2001-04-10 Oravax Passive immunization against Clostridium difficile disease
US6969520B2 (en) 1997-10-20 2005-11-29 Acambis Inc. Active immunization against clostridium difficile disease
US6074689A (en) 1998-03-10 2000-06-13 Immucell Corporation Colonic delivery of protein or peptide compositions
US20020009429A1 (en) 1999-01-29 2002-01-24 Galagen, Inc. Pharmaceutical composition comprising a selected antigen and candida species antigen and methods
US6673574B2 (en) 2000-11-30 2004-01-06 Unigene Laboratories Inc. Oral delivery of peptides using enzyme-cleavable membrane translocators
GB0205206D0 (en) 2002-03-06 2002-04-17 Oxoid Ltd Synthetic peptides
AU2003299527A1 (en) 2002-06-17 2004-06-07 Jimmy D. Ballard Mutant of clostridium difficile toxin b and methods of use
AU2003279750A1 (en) * 2002-06-28 2004-01-19 Nastech Pharmaceutical Company Inc. Compositions and methods for modulating physiology of epithelial junctional adhesion molecules for enhanced mucosal delivery of therapeutic compounds
GB0309126D0 (en) 2003-04-17 2003-05-28 Neutec Pharma Plc Clostridium difficile focussed antibodies
SI2857418T1 (en) * 2004-02-06 2018-01-31 University Of Massachusetts Antibodies against Clostridium difficile toxins and uses thereof
WO2005110465A2 (en) * 2004-04-29 2005-11-24 Glaxosmithkline Istrazivacki Centar Zagreb D.O.O. Oral formulations comprising bone morphogenetic proteins for treating metabolic bone diseases
US20090087478A1 (en) 2004-12-27 2009-04-02 Progenics Pharmaceuticals (Nevada), Inc. Orally Deliverable and Anti-Toxin Antibodies and Methods for Making and Using Them
US7794721B2 (en) 2006-12-13 2010-09-14 Simon Michael R Synthesis of human secretory IgM and the treatment of clostridium difficile associated diseases herewith
CN101363867B (zh) 2008-05-26 2012-12-19 北京庄笛浩禾生物医学科技有限公司 一种艰难梭菌a、b毒素胶体金检测试纸条及其制备方法
JP5740714B2 (ja) 2009-02-20 2015-06-24 ヘルス プロテクション エージェンシー クロストリジウム・ディフィシル（Ｃｌｏｓｔｒｉｄｉｕｍｄｉｆｆｉｃｉｌｅ）毒素に対する抗体
GB0921288D0 (en) 2009-12-04 2010-01-20 Health Prot Agency Therapies for preventing or suppressing clostridium difficile infection

Also Published As

Publication number Publication date
JP2013512889A (ja) 2013-04-18
CA2782639A1 (en) 2011-06-09
WO2011067616A1 (en) 2011-06-09
SG181127A1 (en) 2012-07-30
AU2010325764A1 (en) 2012-06-07
US20130004561A1 (en) 2013-01-03
CN102740889A (zh) 2012-10-17
JP5877161B2 (ja) 2016-03-02
US8921529B2 (en) 2014-12-30
BR112012013496A2 (pt) 2016-08-16
EP2506877B1 (en) 2021-08-04
EP2506877A1 (en) 2012-10-10
MY158712A (en) 2016-11-15
CA2782639C (en) 2019-02-26

Similar Documents

Publication Publication Date Title
GB0921288D0 (en) Therapies for preventing or suppressing clostridium difficile infection
PL3564357T3 (pl) Bakterioterapia zapalenia jelita grubego z clostridium difficile
EP2637191A4 (en) RELAY
ZA201400678B (en) Alpha-amylase variants
GB0909143D0 (en) Messaging system
PL2490735T3 (pl) Automatyczny wstrzykiwacz
PL2283904T3 (pl) System części konstrukcyjnych
GB201016742D0 (en) Clostridium difficile antigens
EP2391894A4 (en) SYSTEM IN RELATIVE TIME
AP3274A (en) Protector for containers
IL213990A0 (en) Compositions for decontamination
EP2510083A4 (en) SPORIC COMPOSITION FOR CLOSTRIDIUM DIFFICILE SPORTS
PL3413000T3 (pl) Układ osłonowy
GB0914700D0 (en) Location system
ZA201109282B (en) Anti notch-antibodies
EP2486890A4 (en) SUPPORT FOR AN IMPLANT
SI2575968T1 (sl) Spojine za zdravljenje bolezni, ki je povezana s clostridium difficile
GB201013048D0 (en) Messaging control system
EP2496718A4 (en) GENOTYPING
IL220114A0 (en) Syringe flange protector
ZA201106615B (en) Messaging system
GB201013060D0 (en) Compounds for the treatment of clostridium difficile associated disease
PL392437A1 (pl) Układ zaworowy
GB201013058D0 (en) Compounds for the treatment of clostridium difficile associated disease
GB201009090D0 (en) Compounds for the treatment of clostridium difficile associated disease

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)